CSANDOMENICO, GFILIPPELLI, BMASSIDDA, AFARRIS, DNATALE, PALMERI S, et al. (2006). “Biweekly oxaliplatin plus capecitabine (OXXEL) versus oxaliplatin plus folinic acid-modulated 5-fluorouracil i.v. bolus (OXAFAFU) in metastatic colorectal carcinoma (MCC): safety interim analysis of a Southern Italy Cooperative Oncology Group (SICOG) phase III trial”. In Proceedings Am Soc Clin Oncol (pp.168s-168s).

“Biweekly oxaliplatin plus capecitabine (OXXEL) versus oxaliplatin plus folinic acid-modulated 5-fluorouracil i.v. bolus (OXAFAFU) in metastatic colorectal carcinoma (MCC): safety interim analysis of a Southern Italy Cooperative Oncology Group (SICOG) phase III trial”

PALMERI, Sergio;
2006-01-01

2006
ABS N.3590
CSANDOMENICO, GFILIPPELLI, BMASSIDDA, AFARRIS, DNATALE, PALMERI S, et al. (2006). “Biweekly oxaliplatin plus capecitabine (OXXEL) versus oxaliplatin plus folinic acid-modulated 5-fluorouracil i.v. bolus (OXAFAFU) in metastatic colorectal carcinoma (MCC): safety interim analysis of a Southern Italy Cooperative Oncology Group (SICOG) phase III trial”. In Proceedings Am Soc Clin Oncol (pp.168s-168s).
Proceedings (atti dei congressi)
CSANDOMENICO; GFILIPPELLI; BMASSIDDA; AFARRIS; DNATALE; PALMERI S; LMAIORINO; GCONDEMI; SLEO; EGRECO; AGAMBARDELLA
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/29366
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact